Abstracts tagged "Interleukins"

Abstract Number: 0818 • ACR Convergence 2023
Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial
Eric Grigsby¹, Stephen D. Collins², Leonard Kapural³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Neurovations Clinical Research, Napa, CA, ²Xalud Therapeutics, Inc., Chicago, IL, ³Center for Clinical Research, Winston-Salem, NC, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. Unfortunately, relatively short…
Abstract Number: 2241 • ACR Convergence 2023
Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielman², Jacques-Eric Gottenberg³, Pierre-Marie Duret², Emmanouil Rampakakis⁴, Mohamed Sharaf⁵, Caren Constantin⁶, vincenza campana⁶ and Laurent Messer⁷, ¹Hôpital de Hautepierre, Strasbourg, France, ²Hôpitaux civils de Colmar, Colmar, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁴JSS Medical Research, Saint-Laurent, QC, Canada, ⁵Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁶Janssen Cilag Medical Affairs, Issy les Moulineaux, France, ⁷Laboratoire Interdisciplinaire en études culturelles (LinCS), Strasbourg, France
Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…
Abstract Number: 0909 • ACR Convergence 2023
Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Joy Park¹, Xiaojing Wang², Aparna Godavarthy¹, Akshay Patel², Krakko Daniel¹, Jessica Nolan¹, Joanne Chilton¹, Bryan Blaker¹ and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 2245 • ACR Convergence 2023
Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
Lars Erik¹, Kim A Papp², Andrew Östör³, Vassilis Stakias⁴, Tshepiso Madihlaba⁴, Ralph Lippe⁵, Ran Liu⁴ and Diamant Thaçi⁶, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ³Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…
Abstract Number: 0937 • ACR Convergence 2023
IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice
Ji Won Yang¹, Kun Hee Lee², Jin Seok Woo², Ha Yeon Jeong², JeongWon Choi², Eui-Jong Kwon¹, Mi-La Cho² and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
Abstract Number: 2254 • ACR Convergence 2023
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng², Ruru Guo³ and Bharat Kumar⁴, ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²The Wright Center for Graduate Medical Education, Scranton, PA, ³Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
Abstract Number: 1266 • ACR Convergence 2023
The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis
Qiong Wu, Quanhu Sheng, Danielle Michell, Marisol Ramirez-Solano, Olivia Posey, Anastasiia Phothisane, Shahensha Shaik, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High-density lipoprotein (HDL) has well-characterized anti-atherogenic cholesterol efflux and antioxidant functions. Another function of HDL uncharacterized in RA is its ability to transport microRNAs…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
Abstract Number: 2475 • ACR Convergence 2023
Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
Kailey Brodeur¹, Meng Liu², Yan Du³, Lauren Henderson¹, Joyce Chang¹, Jane Newburger¹, Peter Nigrovic¹ and Pui Lee⁴, ¹Boston Children's Hospital, Boston, MA, ²Southern Medical University, Boston, MA, ³Harvard medical school, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to the development of coronary artery aneurysms (CAA) in up to…
Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Itay Marmor¹, Rotem Semo Oz², Amir hendel³, Guy Hazan⁴, Kevin Baszis⁵, Anthony French⁵, Cuoghi Edens⁶, Irit Tirosh⁷, Yonatan Butbul Aviel⁸, Liora Harel⁹ and Gil Amarilyo¹⁰, ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Sheba medical center, Herzelyia, Israel, ³Tel Aviv University, Tel Aviv, Israel, ⁴Soroka University Medical Center, Be'er Sheva, Israel, ⁵Washington University School of Medicine, St Louis, MO, ⁶University of Chicago, Chicago, IL, ⁷Sheba Medical Center, Savyon, Israel, ⁸Rambam Medical center, Haifa, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
Abstract Number: 1074 • ACR Convergence 2022
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
Berengere Molina¹, Maria Letizia Urban², Roberto Padoan³, Pavel Novikov⁴, Camille Taillé⁵, Marco Caminati⁶, Christine Christides⁷, nicolas schleinitz⁸, Laura Moi⁹, Vincent Cottin¹⁰, bertrand godeau¹¹, Laurence Bouillet¹², Paolo Fraticelli¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Elena Gelain¹⁸, Giacomo Emmi² and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³University of Padova, Padova, Italy, ⁴Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, ⁵Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, ⁶Verona University Hospital, University of Verona, Verona, Italy, ⁷Avignon hospital, Avignon, France, ⁸Aix Marseille university, AP-HM, Marseille, France, ⁹Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, ¹⁰Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹¹Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, ¹²Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, ¹⁴Akademiska sjukhuset, Uppsala, Sweden, ¹⁵ASST GOM Niguarda, Milano, Italy, ¹⁶Tours University Hospital, Tours, France, ¹⁷Besancon University Hospital, Besançon, France, ¹⁸Meyer Children’s University Hospital of Firenze, Florence, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Mathias Cardner¹, Danny Tuckwell², Anna Kostikova², Pascal Forrer³, Richard Siegel², Alain Marti³, Marc Vandemeulebroecke³ and Enrico Ferrero², ¹Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Novartis Global Drug Development, Basel, Switzerland
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…
Abstract Number: 1147 • ACR Convergence 2022
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Marco A Alba¹, Roser Alba¹, Georgina Espigol Frigolé², Javier Marco Hernández², Sergio Prieto², Marc Corbera-Bellalta³ and Maria C Cid³, ¹IDIBAPS, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clinic, University of Barcelona, Barcelona, Spain
Background/Purpose: Glucocorticoids (GCs) are only effective therapy able to induce disease remission, but most patients relapse when GC are tapered and suffer from GC-related toxicity.…
Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Federica Lumetti¹, Alarico Ariani², Camilla Coccolini³, Carlo Salvarani⁴ and Gilda Sandri⁴, ¹Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, ²Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, ³Università di Modena e Reggio Emilia, Modena, Italy, ⁴Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].